Sangamo Therapeutics Seeks Regulatory Approval for Fabry Disease Gene Therapy
Published on 02/22/2026 at 07:00 | Redaktion boerse-global.de
Sangamo Therapeutics has announced a series of strategic moves, including detailed clinical trial data and the initiation of a regulatory submission for its Fabry disease gene therapy candidate. The company is also bolstering its balance sheet through a new capital raise and has made a change in its financial leadership. These developments aim to strengthen investor confidence in the biotech firm’s long-term financial pathway.
Concurrent with its clinical progress, Sangamo is reinforcing its financial position. The company has launched a public offering of common stock and warrants, which is expected to generate gross proceeds of approximately $25 million. Management has indicated these funds are designated for general corporate working capital purposes.
This Read more...
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
